SEQUANA MEDICAL N.V. |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.71 EUR | -0.58% |
|
+6.21% | -57.25% |
Presentation Operator MessageOperator (Operator)Now welcome to the Sequana KOL call on the cha...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Sequana Medical N.V. is a commercial stage medical device company utilizing its proprietary alfapump® and DSR® (Direct Sodium Removal) technologies to develop innovative treatments for fluid overload in liver disease, malignant ascites and heart failure where diuretics are no longer effective. The alfapump is a fully-implanted, wireless device that automatically pumps fluid from the abdomen into the bladder, where it is removed naturally through urination. The alfapump is CE-marked for the management of refractory ascites due to liver cirrhosis and malignant ascites and has been granted breakthrough device designation by the US FDA with a North American pivotal study underway. DSR is a novel approach to manage sodium and fluid overload through use of a sodium-free infusate administered into the abdominal cavity. The alfapump DSR® combines DSR therapy with the proven alfapump platform and is in clinical development as potential treatment for decompensated heart failure patients.
Calendar
2024-05-22
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
1.72
EUR
Average target price
5.967
EUR
Spread / Average Target
+246.90%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -57.25% | 56.5M | |
| +40.49% | 54.04B | |
| +45.38% | 41.96B | |
| -1.38% | 41.92B | |
| -7.20% | 28.35B | |
| +12.61% | 26.35B | |
| -21.17% | 19B | |
| +7.15% | 13B | |
| +28.79% | 12.28B | |
| +26.06% | 12.19B |
- Stock Market
- Equities
- SEQUA Stock
- News Sequana Medical N.V.
- Transcript : Sequana Medical NV - Special Call